(Reuters) -Only one in four U.S. patients prescribed Novo Nordisk’s Wegovy or Ozempic for weight loss were still taking the ...
Evidence that many people may stop their use of obesity drugs not long after starting casts doubt on sustainability of weight ...
Noom, Calibrate, and Embla tell customers they can stop taking GLP-1s and keep off the weight they’ve lost. Doctors and drug manufacturers disagree.
THURSDAY, July 11, 2024 (HealthDay News) -- Three of four patients stop taking Ozempic or Wegovy two years after being ...
Patients who took the frequently prescribed diabetes and weight-loss drugs Ozempic and Wegovy faced a greater risk of a ...
India’s CDSCO has approved Eli Lilly's Tirzepatide. It will make its debut in the Indian market under the brand name Mounjaro ...
Pfizer doesn't currently produce any anti-obesity medicines, but it wants to do so. However, its most mature program on that ...
Find out more about Pfizer's oral GLP-1 candidate danuglipron, as the company aims to compete in the obesity market.
The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lilly and Novo Nordisk that will offer patients a more convenient alternative to ...
But it’s not two per cent; as many as 65 per cent of Canadians have weight-related health risk factors. Put half — 10 million ...
After years of college and medical school research, I’d never once gotten emotional while reading interviews from research participants. That is, until I came across an interview of one of ...
Only one in four U.S. patients prescribed Novo Nordisk’s Wegovy or Ozempic for weight loss were still taking the popular ...